Cite
HARVARD Citation
Le Tourneau, C. et al. (n.d.). 1047PDPembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals of oncology. p. . [Online].